---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-103942"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:43:02.306162+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics completes enrollment of 188 patients in Phase 2 DeFianCe study of DKN-01 for CRC

## Summary
- Enrolled 188 patients in randomized controlled Part B of DeFianCe study (NCT05480306).
- Evaluates DKN-01 + bevacizumab + chemo as second-line therapy for advanced colorectal cancer.
- Primary endpoint: progression-free survival overall and in left-sided CRC subpopulation.
- Initial data from Part B expected in mid-2025; Part A showed encouraging response rates.
- Study expanded from 130 to 188 patients, reflecting investigator and patient interest.

## SEC filing metadata
- accession: 0001104659-24-103942
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465924103942/0001104659-24-103942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465924103942/tm2425162d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-103942
- JSON: https://secwatch.observer/filing/0001104659-24-103942.json
- Plain text: https://secwatch.observer/filing/0001104659-24-103942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.